126 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28228366	2	Leupeptazin, a highly modified tripeptide isolated from cultures of a Streptomyces sp. inhibits cathepsin K.	University Of British Columbia
27498895	6	Affinity Crystallography: A New Approach to Extracting High-Affinity Enzyme Inhibitors from Natural Extracts.	University Of British Columbia
27214508	43	Straightforward synthesis of 2,4,6-trisubstituted 1,3,5-triazine compounds targeting cysteine cathepsins K and S.	Cnrs
27690432	75	Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).	Charles River Discovery Research Services
26985300	110	Cathepsin B Inhibitors: Combining Dipeptide Nitriles with an Occluding Loop Recognition Element by Click Chemistry.	University Of Bonn
26280490	17	Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors.	National Institute Of Chemistry
25571794	40	Structure-based design and optimization of potent inhibitors of the adenoviral protease.	Novartis Institute For Biomedical Research
24592859	59	Cathepsin C inhibitors: property optimization and identification of a clinical candidate.	Astrazeneca
23350811	57	Docking-based virtual screening of covalently binding ligands: an orthogonal lead discovery approach.	Msd Animal Health Innovation
24900293	78	Discovery of novel cyanamide-based inhibitors of cathepsin C.	TBA
19962796	64	3D QSAR studies on ketoamides of human cathepsin K inhibitors based on two different alignment methods.	Chinese Academy Of Sciences
19616430	120	Design of selective Cathepsin inhibitors.	Astrazeneca
16546382	100	Keto-1,3,4-oxadiazoles as cathepsin K inhibitors.	Celera Genomics
9804696	2	Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites.	Smithkline Beecham Pharmaceuticals
9767629	8	Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic.	Smithkline Beecham Pharmaceuticals
23122525	9	Fluorescent nitrile-based inhibitors of cysteine cathepsins.	University Of Bonn
22984809	111	Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors.	Astrazeneca
22742641	113	(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.	Astrazeneca
22686657	60	Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F.	University Of Bonn
22858142	121	Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.	Astrazeneca
21128614	76	Structural optimization of azadipeptide nitriles strongly increases association rates and allows the development of selective cathepsin inhibitors.	University Of Bonn
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University Of Florida
18375120	45	New chemotypes for cathepsin K inhibitors.	Novartis Institutes For Biomedical Research
18053726	364	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.	Johnson & Johnson Pharmaceutical Research & Development
18226527	80	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.	Merck Frosst Centre For Therapeutic Research
16380250	31	4-Aminophenoxyacetic acids as a novel class of reversible cathepsin K inhibitors.	Sankyo
15713380	16	cis-6-oxo-hexahydro-2-oxa-1,4-diazapentalene and cis-6-oxo-hexahydropyrrolo[3,2-c]pyrazole based scaffolds: design rationale, synthesis and cysteinyl proteinase inhibition.	Amura Therapeutics
21733692	56	Azepanone-based inhibitors of human cathepsin S: optimization of selectivity via the P2 substituent.	Glaxosmithkline
21232956	10	Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.	Merck Frosst Centre For Therapeutic Research
21227690	68	1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors: separation of desired cellular activity from undesired tissue accumulation through optimization of basic nitrogen pka.	Merck Research Laboratories
21041084	102	Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease.	Merck Research Laboratories
21030256	61	Trifluoromethylphenyl as P2 for ketoamide-based cathepsin S inhibitors.	Merck Research Laboratories
20843687	60	Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG.	Merck Research Laboratories
19841155	29	MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.	Merck Research Laboratories
20598883	83	6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors.	Merck Research Laboratories
20594841	123	2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors.	Merck Research Laboratories
20580231	21	4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important.	Merck Research Laboratories
20218623	68	Emerging targets in osteoporosis disease modification.	Amgen
20153187	32	Dioxo-triazines as a novel series of cathepsin K inhibitors.	Schering-Plough
20149657	53	Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors.	Schering-Plough
20061146	12	The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.	Merck Frosst Centre For Therapeutic Research
19231183	44	5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.	Astrazeneca
19124252	141	Solid-phase parallel synthesis and SAR of 4-amidofuran-3-one inhibitors of cathepsin S: effect of sulfonamides P3 substituents on potency and selectivity.	Medivir
19117756	27	Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors.	Merck Frosst Centre For Therapeutic Research
18662880	56	4-Amino-2-cyanopyrimidines: novel scaffold for nonpeptidic cathepsin S inhibitors.	Novartis Institutes For Biomedical Research
18572405	85	Discovery of selective and nonpeptidic cathepsin S inhibitors.	Novartis Institutes For Biomedical Research
18571402	24	Effect of novel N-cyano-tetrahydro-pyridazine compounds, a class of cathepsin K inhibitors, on the bone resorptive activity of mature osteoclasts.	Korea Research Institute Of Chemical Technology
18570365	29	The many roles for fluorine in medicinal chemistry.	Merck Research Laboratories
18313933	18	Substrate optimization for monitoring cathepsin C activity in live cells.	Genomics Institute Of The Novartis Research Foundation
11975521	2	Haploscleridamine, a novel tryptamine-derived alkaloid from a sponge of the order haplosclerida: an inhibitor of cathepsin K.	Millennium Pharmaceuticals
11975520	3	A new dimeric dihydrochalcone and a new prenylated flavone from the bud covers of Artocarpus altilis: potent inhibitors of cathepsin K.	Millennium Pharmaceuticals
17911019	50	Novel scaffold for cathepsin K inhibitors.	Novartis Institutes For Biomedical Research
17544269	30	Primary amides as selective inhibitors of cathepsin K.	Merck Frosst Centre For Therapeutic Research
17196818	90	Bicyclic carbamates as inhibitors of papain-like cathepsin proteases.	The Genomics Institute Of The Novartis Research Foundation
16750630	28	Design and synthesis of tetracyclic nonpeptidic biaryl nitrile inhibitors of cathepsin K.	Celera Genomics
16376075	28	Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.	Glaxosmithkline
16290936	69	Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?	Glaxosmithkline
16250645	35	Azepanone-based inhibitors of human cathepsin L.	Glaxosmithkline
16154747	37	Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K.	Merck Frosst Centre For Therapeutic Research
15993587	11	Ketoheterocycle-based inhibitors of cathepsin K: a novel entry into the synthesis of peptidic ketoheterocycles.	Glaxosmithkline
15982880	86	P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.	Glaxosmithkline
15896958	32	Acyclic cyanamide-based inhibitors of cathepsin K.	Glaxosmithkline
15837295	55	A structural screening approach to ketoamide-based inhibitors of cathepsin K.	Glaxosmithkline
15780613	28	Novel and potent cyclic cyanamide-based cathepsin K inhibitors.	Glaxosmithkline
15537340	27	Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K.	Novartis Institutes For Biomedical Research
15456249	22	Ketoamide-based inhibitors of cysteine protease, cathepsin K: P3 modifications.	Glaxosmithkline
15456248	33	Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K.	Glaxosmithkline
15341947	57	Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions.	Glaxosmithkline
15261289	38	Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors.	Merck Frosst Centre For Therapeutic Research
15177446	41	Exploration of the P2-P3 SAR of aldehyde cathepsin K inhibitors.	Glaxosmithkline
15109647	11	Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K.	Glaxosmithkline
14741275	27	Design of small molecule ketoamide-based inhibitors of cathepsin K.	Glaxosmithkline
14736240	57	Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.	Glaxosmithkline
14684342	39	Exploration of the P1 SAR of aldehyde cathepsin K inhibitors.	Glaxosmithkline
14684338	44	P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl alpha-ketoamide based HCV protease inhibitors.	Eli Lilly
14684304	41	(4-Piperidinylphenyl)aminoethyl amides as a novel class of non-covalent cathepsin K inhibitors.	Amgen
12781193	36	3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P2 elements for selectivity.	Ligand Pharmaceuticals
12781182	81	Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating P1' substituents.	Novartis Pharma
12467634	67	3-Acylamino-azetidin-2-one as a novel class of cysteine proteases inhibitors.	Currently Naeja Pharmaceutical
12431059	27	Design of noncovalent inhibitors of human cathepsin L. From the 96-residue proregion to optimized tripeptides.	National Research Council Of Canada
12419374	45	6-Acylamino-penam derivatives: synthesis and inhibition of cathepsins B, L, K, and S.	Currently Naeja Pharmaceutical
12419373	18	Design and synthesis of 6-substituted amino-4-oxa-1-azabicyclo[3,2,0]heptan-7-one derivatives as cysteine proteases inhibitors.	Currently Naeja Pharmaceutical
12270191	36	General solid-phase method to prepare novel cyclic ketone inhibitors of the cysteine protease cruzain.	University Of California
12270170	42	Novel route to the synthesis of peptides containing 2-amino-1'-hydroxymethyl ketones and their application as cathepsin K inhibitors.	Celera
12213061	23	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases.	University Of Gda£?Sk
12036343	24	Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors.	TBA
11677133	14	Discovery and parallel synthesis of a new class of cathepsin K inhibitors.	Bayer Research Center
11311061	40	Azepanone-based inhibitors of human and rat cathepsin K.	Glaxosmithkline
11206458	14	Diastereoselective synthesis, activity and chiral stability of cyclic alkoxyketone inhibitors of cathepsin K.	Smithkline Beecham Pharmaceuticals
11206457	29	Solid-phase synthesis of cyclic alkoxyketones, inhibitors of the cysteine protease cathepsin K.	Smithkline Beecham Pharmaceuticals
11141092	85	Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.	Merck Frosst Centre For Therapeutic Research
10450951	3	Design and synthesis of diaminopyrrolidinone inhibitors of human osteoclast cathepsin K.	Smithkline Beecham Pharmaceuticals
9733481	31	Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K.	Smithkline Beecham Pharmaceuticals
7650671	15	Vinyl sulfones as mechanism-based cysteine protease inhibitors.	Khepri Pharmaceuticals
23356427	16	Synthesis and carbonic anhydrase inhibitory properties of 1,3-dicarbonyl derivatives of methylaminobenzene-sulfonamide.	Sakarya University
21635213	8	In vitro effects of some anabolic compounds on erythrocyte carbonic anhydrase I and II.	Balikesir University
10455251	10	RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist.	Roche Bioscience
1397049	24	NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists.	Novo Nordisk
15734651	135	A neoceptor approach to unraveling microscopic interactions between the human A2A adenosine receptor and its agonists.	National Institutes Of Health
19620011	80	Rational design, synthesis and characterization of potent, non-peptidic Smac mimics/XIAP inhibitors as proapoptotic agents for cancer therapy.	Universita Degli Studi Di Milano
15225699	27	Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors.	Eli Lilly